Introduction. Pulmonary embolism (PE) is a lifethreatening pathological condition caused by derangement of blood flow in the pulmonary artery due to embolism by thrombi mainly from the system of the lower vena cava. It is the most dangerous complication of venous thrombosis of the lower extremities [1, 3] . The incidence ranges from 75 to 269 cases per 100,000 population per year in Western Europe, North America, Australia, and Latin America [2, 3] .
PE occupies a special position among other critical conditions. And to date, a number of problems of diagnosis, treatment and prevention remains unresolved. For reliable diagnosis, angiography or computer tomography is required. Multi-spinal computer angiopulmonography (MSCT APG) allows not only to establish correct diagnosis, but also to conduct differential diagnosis between thrombotic and non-thrombotic embolism [4] . Effective treatment of massive pulmonary embolism is possible only through the use of potentially dangerous thrombolytics, or by performing thrombembolectomy from the pulmonary artery with an artificial blood circulation device. Even in the developed countries, the level of mortality due to PE remains high and ranges from 7 to 11 % [5] . Despite preventive measures, PE regularly occurs in surgical and therapeutic hospitals, and there is also a high level of recurrent PE in the distant period after discharge. Thus, improvement of the treatment of patients with PE remains one of the most important problems of modern medicine [3] .
Aim.
To improve the methods of diagnosis and treatment of PE by analyzing the ten-year experience of care of patients suffering from this abnormality.
Materials and methods. To study the results of diagnosis and treatment of acute PE, inpatient medical records for the period from 2008 to 2018 were processed.
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thrombolytic therapy (in the absence of contraindications) was prescribed, and 5 (1.1 %) patients underwent thromboembolectomy from the right heart and pulmonary artery branches. In unstable hemodynamics, hypotension, and high risk of bleeding, alteplase was preferred due to its faster action. In other cases, the choice of thrombolytic was arbitrary, given the availability of drugs in the hospital.
In 358 (75.8 %) patients, a source of PE was detected -deep veins thrombosis of the lower extremities. Other causes of PE were: varicose of the lower limb veins -54 (11.4 %), thrombosis of the cavities of the right heart -5 (1.1 %), thrombosis of the lower vena cava -5 (1.6 %). In 85 (18.4 %) patients, there were no signs of thrombosis of the system of the lower vena cava of the right heart or varicose of the lower extremities.
For 10 years, with the introduction of diagnostic MSCT APG, there was gradual displacement of traditional APG for the final diagnosis of PE.
MSCT APG has advantages over the APG such as minimum invasion, the ability to detect acute and chronic diseases and cancer abnormality of the lungs due to visualization of all the chest organs. Also, MSCT APG enables to differentiate acute and chronic PE. All this contributed to the fact that the MSCT APG at the present time occupies a leading position in PE diagnosis.
According to the survey, the patients were distributed by the disease severity as follows: 268 (56.8 %) patients with massive, 116 (24.6 %) with submassive, 88 (18.6 %) with non-massive PE.
Favorable treatment results were obtained in 433 (91.7 %) patients with PE, who were discharged from the hospital for outpatient treatment. On discharge, long-term use of anticoagulants vitamin K antagonists (VKA) with the control of international normalized ratio (INR) or prothrombin index (PI) was recommended. Since 2012, NOACs are used for the secondary prevention.
Thirty nine (8.2 %) patients died within 10 years. Distribution of the causes of fatal cases was as follows: PE recurrence in 17 (43.6 %) cases, progressive heart failure in 14 (35.9 %) and bleeding in 8 (20.5 %) cases.
The cases of death due to PE recurrences, as well as from bleeding, should be considered more closely as those that could be warned.
Seventeen (43.6 %) patients died from PE recurrence; two (5.1 %) cases were reliably confirmed by APG, in other cases the recurrence was clinically detected. Of all 17 patients who died from PE recurrence, only one (5.9 %) had floating thrombus before the recurrence; in two (11.8 %) patients, no signs of unstable blood clots were detected. Other 14 (82.4 %) patients did not undergo ultrasound examination of the veins of lower extremities due to inaccessibility of this study and, accordingly, there was no information about the presence of dangerous blood clots.
Eight (1.7 %) patients died from severe hemorrhage due to thrombolytics. Of these 8 patients, 4 (50 %) patients died after streptokinase administration, 3 (37.5%) after alteplase and 1 (12,5 %) after heparin therapy. By the source of fatal bleeding, the patients were distributed as follows: 2 (25 %) patients died due to gastrointestinal bleeding; 2 (25 %) due to hemorrhagic stroke; 2 (25 %) due to pulmonary bleeding; 1 (12.5 %) due to bleeding from surgical wounds; 1 (12.5%) due to bleeding from the oro-and nasopharynx.
For 10 years, there were 14 (36 %) fatal cases due to cardiac and respiratory failure progression. The average age of these patients was 66 ± 14 years, while the average age of surviving patients was 60 ± 13.6, p = 0.09: there is a trend towards older age in patients who died. At the same time, the dead patients had higher average duration of the disease before being hospitalized. In discharged patients duration of the disease was significantly longer in the dead patients: 5.9 ± 13.6 days in the discharged patients and 10.5 ± 12.5 days in the dead, p = 0.02.
As may be seen from the chart, bleeding and PE recurrence remain the factors leading to fatal outcomes.
After transfer from the intensive care unit, 339 (78.3 %) patients were assigned to VKA, and 94 (21.7 %) to NOACs. Discussion. Analysis of the dynamics of the number of patients with PE for ten years revealed the increase in the number of patients from 2008 to 2010, and further the number of patients varied in the range from 40 to 60. This dynamics may be explained by the improvement of PE diagnosis due to the wider implementation of the MSCT APG since 2010. As the MSCT APG is less invasive and does not require special skills, the possibility to detect PE has appeared in all the institutions where CT scanners and related software are available.
Due to the use of the embolism index in MSCT APG and Miller's index in APG, the choice between anticoagulant and thrombolytic therapy was simplified. This allowed avoiding unreasonable risk in the use of thrombolytics in non-massive PE and reducing the level of fatal hemorrhagic intracranial hemorrhage to 0.4 % with global mortality of up to 2 % [3] .
As a result of treatment, 433 (91.7 %) patients were discharged with improvement with normal hemodynamics and oxygen saturation. Thus, the results of PE diagnosis and treatment was satisfactory. Mortality rate of 8.2 % corresponds to the global level from 7 to 11 % [5] , and there is no trend to increase. Taking into account eight cases of death due to fatal blood loss, the sources of possible bleeding should be identified more carefully. If these are detected, fibrinolytic therapy should be avoided and anticoagulants and surgical treatment should be used. In view of 14 (2.9 %) cases of recurrent PE that resulted in death, ultrasound examination of the lower limb veins should be performed as soon as possible to detect embolus threatening floating thrombi. Conclusions 1. MSCT APG has shown high accuracy in detected PE, as well as additional capabilities for the detection of concomitant pathology and differential diagnosis. 2. Thrombolytic therapy quickly and reliably improves general condition of patients. 3. First of all, it is necessary to identify embolus threatening thrombi as soon as possible to prevent recurrence. 4. Both Vitamin K antagonists (VKA) and NOACs are feasible for secondary prevention of PE.
